Veracyte Showcases Decipher & MRD Test Insights in Urologic Cancers at EAU25
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, has announced that eight abstracts highlighting the performance and clinical utility of its Decipher and minimal residual disease (MRD) tests will be presented at the 40th Annual European Association of Urology Congress (EAU25). The event, taking place from March 21-24 at IFEMA Madrid in Spain, will showcase data supporting the clinical benefits of these tests in prostate and bladder cancer treatment.
“These new data reinforce the impact our Decipher tests are having on patient care in prostate and bladder cancers and how our whole-transcriptome approach is enabling us to partner with researchers to fuel new insights into the underlying biology of these diseases,” said Philip Febbo, M.D., Veracyte’s Chief Scientific and Medical Officer. “We are similarly deploying a whole-genome approach with our MRD testing platform and are excited to see data from the TOMBOLA trial at EAU25 that reinforce the strong performance of our MRD platform for muscle-invasive bladder cancer. We plan to launch a test for this indication next year.”
Decipher and MRD Test Presentations at EAU25
Prostate Cancer:
- Transcriptomic profiling of the tumor immune microenvironment reveals prognostic markers in mCRPC patients treated with LuPSMA therapy
- Presenter: Analena Handke, M.D., Ruhr University Bochum, Germany
- Format: Poster (#P195)
- Date/Time: March 22, 11:30-12:00 CET
- Location: Green Area, EGPT 2
- Transcriptomic expression patterns in very high-risk Decipher >0.85
- Presenter: Nicole Handa, M.D., Northwestern University, USA
- Format: Oral (#A0587)
- Date/Time: March 23, 15:30-16:10 CET
- Location: Purple Area, Room 1
Bladder Cancer:
- Discrepancy between clinical and pathological stage after radical cystectomy: Results from a nation-wide prospective cohort study
- Presenter: Joep J. de Jong, M.D., Erasmus University Medical Center, Netherlands
- Format: Oral (#A0122)
- Date/Time: March 21, 16:15-16:40 CET
- Location: Pink Area, N103
- A non-coding RNA-based classifier for favorable outcomes in clinically organ-confined bladder cancer
- Presenter: Joep J. de Jong, M.D., Erasmus University Medical Center, Netherlands
- Format: Oral (#A0504)
- Date/Time: March 23, 14:35-15:15 CET
- Location: Pink Area, N101
- Molecular characterization of residual muscle-invasive bladder cancer identifies a scar-like genomic profile with favorable prognosis after neoadjuvant chemo and immunotherapy
- Presenter: Joep J. de Jong, M.D., Erasmus University Medical Center, Netherlands
- Format: Oral (#A0508)
- Date/Time: March 23, 14:35-15:15 CET
- Location: Pink Area, N101
- Gene expression signatures of immune infiltration portend differential response to sequential intravesical Gemcitabine and Docetaxel vs. Bacillus Calmette-Guerin in high-risk non-muscle-invasive bladder cancer
- Presenter: Joep J. de Jong, M.D., Erasmus University Medical Center, Netherlands
- Format: Oral (#A0674)
- Date/Time: March 23, 17:15-17:50 CET
- Location: Pink Area, N101
- The Estrogen Response Pathway as a putative predictive biomarker of neoadjuvant Pembrolizumab benefit in muscle-invasive bladder carcinoma
- Presenter: Joep J. de Jong, M.D., Erasmus University Medical Center, Netherlands
- Format: Poster (#P598)
- Date/Time: March 24, 13:10-14:00 CET
- Location: Green Area, EGPT 1
Minimal Residual Disease (MRD):
- Comparison of ctDNA detection methods for monitoring minimal residual disease in bladder cancer: Insights from the TOMBOLA trial
- Presenter: Iver Nordentoft, Ph.D., Aarhus University, Denmark
- Format: Oral (#A0162)
- Date/Time: March 22, 10:32-11:15 CET
- Location: Purple Area, Room 1
About Veracyte’s Decipher and MRD Tests
Decipher Prostate
The Decipher Prostate Genomic Classifier is a 22-gene test designed using RNA whole-transcriptome analysis and machine learning to inform treatment decisions for prostate cancer patients. The test evaluates biopsy or surgically resected samples and provides an accurate metastasis risk assessment, allowing physicians to tailor treatment plans. The Decipher Prostate test has been validated in over 85 studies, involving more than 200,000 patients, and is the only gene expression test included in the NCCN® Guidelines for prostate cancer risk stratification.
Decipher Bladder
The Decipher Bladder Genomic Classifier is a 219-gene test developed using RNA whole-transcriptome analysis and machine learning. It assists in determining treatment intensity following bladder cancer diagnosis. The test classifies bladder tumors into five molecular subtypes, each associated with distinct tumor biology and clinical implications. By offering insights into the potential benefits of neoadjuvant chemotherapy and the likelihood of non-organ-confined disease at the time of surgery, it supports personalized treatment decisions.
About Veracyte
Veracyte (Nasdaq: VCYT) is a global diagnostics company focused on transforming cancer care worldwide. Through its Veracyte Diagnostics Platform, the company delivers high-performance cancer tests powered by extensive genomic and clinical data, bioinformatics, AI capabilities, and rigorous evidence generation. This ensures durable reimbursement and guideline inclusion for its tests while driving continued innovation. More information can be found at www.veracyte.com, and updates can be followed on X (formerly Twitter) @veracyte.
